Fragment 176-191 & CJC-1295 & Ipamorelin Blend
A research blend combining Fragment 176-191 (selective lipolytic hGH fragment) with CJC-1295 and ipamorelin for combined fat loss and GH-stimulating research.
Community Rating
No ratings yet
Compound Profile
Fragment 176-191 & CJC-1295 & Ipamorelin Blend
Key Data
Research reference only
Research Focus
Preclinical data
⚠ Research & Educational Use Only. Fragment 176-191 & CJC-1295 & Ipamorelin Blend is a research chemical documented here for scientific education. All information references peer-reviewed literature and preclinical/clinical study data. Not for human consumption. Not medical advice. Consult a licensed researcher or healthcare professional before any laboratory use.
- Selective lipolysis from Fragment 176-191 without IGF-1 elevation
- Synergistic GH release from CJC-1295 + ipamorelin
- Combined fat loss + anabolic GH axis stimulation
- Fragment 176-191 & CJC-1295 & Ipamorelin Blend is not FDA-approved for human use. It is a research chemical for scientific study only.
Research At a Glance
- Selective lipolysis from Fragment 176-191 without IGF-1 elevation
- Synergistic GH release from CJC-1295 + ipamorelin
- Combined fat loss + anabolic GH axis stimulation
- Fragment 176-191 preserves insulin sensitivity while CJC/ipamorelin elevates IGF-1
In Plain English
Simple summaryThink of Fragment 176-191 & CJC-1295 & Ipamorelin Blend as a signalling molecule your body already recognises, it doesn't introduce anything foreign, it tells specific cells to do things they're already capable of doing, just more efficiently.
- Selective lipolysis from Fragment 176-191 without IGF-1 elevation
- Synergistic GH release from CJC-1295 + ipamorelin
- Combined fat loss + anabolic GH axis stimulation
The full scientific detail, mechanisms, citations, and dosing data, follows below.
What is Fragment 176-191 & CJC-1295 & Ipamorelin Blend?
Tap any underlined term for an instant definition.
The Fragment 176-191 & CJC-1295 & Ipamorelin Blend is a three-component research preparation designed to combine selective fat loss (via Fragment 176-191) with synergistic GH stimulation (via CJC-1295 + ipamorelin). This combination is specifically designed for body recomposition research, targeting simultaneous fat reduction and lean mass preservation.
What It Is
- Fragment 176-191: C-terminal hGH fragment with selective lipolytic activity, no GH receptor binding, no IGF-1 elevation
- CJC-1295 (no DAC): GHRH analogue for GHRHR-mediated pulsatile GH release
- Ipamorelin: selective GHS-R1a agonist for complementary GH stimulation
- Designed for simultaneous fat loss (Fragment mechanism) + anabolic GH support (CJC-1295 + ipamorelin)
How It Works
- Fragment 176-191 activates beta-adrenergic receptor-like site on adipocytes, stimulating lipolysis and inhibiting lipogenesis independently of GH receptor
- CJC-1295 + ipamorelin provide synergistic GH pulses (3-4x either alone), elevating IGF-1 for lean mass support
- The combination produces fat loss without the insulin resistance of full hGH, while the GH component supports muscle preservation
Key Research Findings
- Fragment 176-191 alone: 18-30% body fat reduction in obese rodent models over 4-6 weeks
- CJC-1295 + ipamorelin component: 2-3 kg lean mass increase, 2% fat reduction at 6 months
- No published head-to-head data on the triple combination vs each component
Dosing From the Literature
- Fragment 176-191: 200-500 mcg subcutaneous, morning fasted
- CJC-1295 (no DAC): 100-200 mcg per injection
- Ipamorelin: 200-300 mcg per injection
Storage and Handling
- Lyophilised: 2-8 degrees C; 24 months
- Reconstituted: 2-8 degrees C; use within 21 days
Key Research Benefits
Documented effects observed in preclinical and clinical studies on Fragment 176-191 & CJC-1295 & Ipamorelin Blend. See all Peptide Blends peptides for comparison.
Side Effects & Risks
Adverse effects reported in the research literature. All data sourced from preclinical and clinical study reports. View all peptides' side effects →
Dosing Data from the Literature
Doses referenced below are sourced from published preclinical and clinical studies. Use the peptide dose calculator to convert these values to injection volume.
Administration in Research Settings
Standard reconstitution and administration methodology for laboratory research use.
Subcutaneous injection. Best administered in the morning fasted for lipolytic effects.
Medical Expert Videos
Physicians, researchers, and pharmacologists explain Fragment 176-191 & CJC-1295 & Ipamorelin Blend, covering mechanisms of action, clinical context, and study findings.
Videos sourced from YouTube search. KnowYourPeptide does not endorse any individual creator. For research education only.
The Bottom Line
Fragment 176-191 & CJC-1295 & Ipamorelin Blend has a growing body of preclinical evidence and a well-characterised safety profile in research settings. The most-studied application is: selective lipolysis from fragment 176-191 without igf-1 elevation.
The most commonly reported side effect in research subjects is each component's individual side effects apply. It is a research chemical, not approved for human use.
Frequently Asked Questions
Explore Further
Quick Reference
More in Peptide Blends
- Sermorelin & Ipamorelin Blend
- Sermorelin & GHRP-2 Blend
- Sermorelin & GHRP-6 Blend
- Sermorelin & GHRP-6 & GHRP-2 Triple Blend
Research Use Only
This information is for educational research purposes only. This is not medical advice. Consult a qualified healthcare professional.